Internal Medicine, Endocrinology, Diabetes, & Metabolism · Sugar Land, TX
NPI
1295752004
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
16537 Southwest Fwy Ste 300
Sugar Land, TX, 77479
Phone (832) 532-7514
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
1,611 services
Medicare patients, 2024
600
Average age 74
Drug cost, 2024
$3.8M
9,703 prescriptions
Company payments, 2025
$4,842
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vidhya Subramanian was code 99214 (office e&m - established), 777 times for 465 patients. In total Vidhya Subramanian billed 1,611 services in 11 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 777 | 465 | $83.35 | $65K |
| 95251 Test - Miscellaneous | Office | 228 | 128 | $24.68 | $5,627 |
| 99213 Office E&M - Established | Office | 127 | 110 | $56.11 | $7,126 |
| 99204 Office E&M - New | Office | 33 | 33 | $104.03 | $3,433 |
| 99212 Office E&M - Established | Office | 14 | 13 | $42.71 | $598 |
By year: 2022 $78K for 960 services; 2023 $89K for 1,291 services; 2024 $85K for 1,611 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vidhya Subramanian prescribed most often to Medicare patients was Levothyroxine Sodium, with 876 prescriptions and refills. In total Vidhya Subramanian wrote 9,703 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 876 | 2,532 | 275 | $9,664 |
| Ozempic Semaglutide | 631 | 1,019 | 143 | $952K |
| Metformin Hcl Generic | 407 | 1,184 | 121 | $3,965 |
| Metformin Hcl Er Metformin Hcl | 394 | 1,148 | 127 | $5,192 |
| Jardiance Empagliflozin | 350 | 749 | 96 | $420K |
| Synthroid Levothyroxine Sodium | 348 | 957 | 106 | $28K |
| Atorvastatin Calcium Generic | 346 | 1,019 | 114 | $2,890 |
| Rosuvastatin Calcium Generic | 295 | 869 | 102 | $5,871 |
| Humalog Kwikpen U-100 Insulin Lispro | 283 | 524 | 89 | $113K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 245 | 532 | 96 | $50K |
| Mounjaro Tirzepatide | 242 | 387 | 55 | $403K |
| Losartan Potassium Generic | 178 | 514 | 54 | $1,889 |
| Novolog Flexpen Insulin Aspart | 172 | 323 | 68 | $66K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 171 | 465 | 76 | $21K |
| Lisinopril Generic | 160 | 475 | 49 | $1,394 |
Brand drugs: 4,382 claims; generic drugs: 4,855 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vidhya Subramanian $4,842 ($4,842 in general payments such as food, travel and fees) from 35 companies. The largest payer was Novo Nordisk Inc with $557.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 30 | $557 |
| Amgen Inc. AMGN | 27 | $417 |
| Insulet Corporation PODD | 14 | $378 |
| Avvisto Therapeutics, LLC | 6 | $293 |
| Corcept Therapeutics CORT | 14 | $282 |
| Tandem Diabetes Care, Inc. TNDM | 10 | $262 |
| Ascendis Pharma Endocrinology Inc ASND | 10 | $248 |
| Lilly USA, LLC LLY | 14 | $240 |
| Dexcom, Inc. DXCM | 21 | $220 |
| Alexion Pharmaceuticals, Inc. AZN | 4 | $209 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.